# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-062301
Filing Date
2023-05-18
Accepted
2023-05-18 17:00:17
Documents
5
Period of Report
2023-06-28

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm232158-3_def14a.htm | DEF 14A | 793216
2 | GRAPHIC | lg_protalix-4c.jpg | GRAPHIC | 22515
3 | GRAPHIC | sg_eyalrubin-bw.jpg | GRAPHIC | 10220
4 | GRAPHIC | px_protalixproxy1pg01-bwlr.jpg | GRAPHIC | 536609
5 | GRAPHIC | px_protalixproxy1pg02-bwlr.jpg | GRAPHIC | 676377
| Complete submission text file | 0001104659-23-062301.txt |  | 2330778

Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 23936914
SIC: 2836 Biological Products, (No Diagnostic Substances)